Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by G1945Von Feb 03, 2023 2:29pm
86 Views
Post# 35265555

RE:RE:CEO.CA @Yoyo

RE:RE:CEO.CA @Yoyo
GrahamB wrote: We are told by a poster on another board that GA told them that NICE was a "clerical error"

Exactly how doesn an evidenced based process, by experts, including one consultant paid by VPT change this, based on a clerical  error?

I had predicted the NICE outcome, and stand by my overall conclusion

We will wait and see....

 

 

•"Experts advised that more evidence is needed before VMS+ can be routinely used in the NHS. Experts disagreed about where VMS+ would provide the most benefit in the care pathway. One expert felt that VMS+ would provide little additional value than existing technologies."

Source:NICE Experts Comments

 

 

Source:Abstracted from UK NICE MIB Ventripoint 


WHAT did the Uk NICE expert panel(included a VPT paid consultant say about VPT?

 

"Two experts stated that, as VMS+ can be used with standard 2D echocardiography equipment, it requires less retraining of staff than current available 3D systems. However, the experts noted that VMS+ is more time consuming than fully automated echocardiograph systems, as it requires healthcare professionals to manually plot points on anatomical landmarks of the heart. Two experts felt that VMS+ would cost slightly more than current standard care due to the additional time it could take to complete an echocardiogram." 

 

•"Experts advised that more evidence is needed before VMS+ can be routinely used in the NHS. Experts disagreed about where VMS+ would provide the most benefit in the care pathway. One expert felt that VMS+ would provide little additional value than existing technologies."

Source:NICE Experts Comments

 

 

Source:Abstracted from UK NICE MIB Ventripoint 



Graham,

I (and most I'm sure) rather follow Dr. George Adams and his track record rather than your continual biased rambling.

G1945V

<< Previous
Bullboard Posts
Next >>